WHAT IS CLAIMED IS:

1. Use of

a) cells expressing a chimeric antigen receptor (CAR) in the manufacture of a first medicament, wherein the CAR comprises a D domain comprising the amino acid sequence of SEQ ID NO: 850, and

b) an adapter comprising (i) the amino acid sequence of SEQ ID NO: 1118 and (ii) a D domain that binds to BCMA in the manufacture of a second medicament,

wherein the first and second medicaments are to be used in combination therapy to treat a BCMA-related cancer, wherein the first medicament is to be administered at a dose of 20×10^6 to 500×10^6 cells expressing the CAR and at least one dose of the second medicament is to be administered.

2. The use of claim 1, wherein the D domain comprises the amino acid sequence of SEQ ID NO: 201.

3. The use of claim 1, wherein the first medicament is to be administered at a dose of about $100x10^6$ cells expressing the chimeric antigen receptor.

4. The use of claim 1, wherein the second medicament is to be administered at a dose of from 5 μg/kg to 5 mg/kg of the adapter.

5. The use of claim 1, wherein the second medicament is to be administered at a dose of about 0.2 mg/kg of the adapter.

6. The use of claim 1, wherein the second medicament is to be administered at a dose of about 0.07 mg/kg of the adapter.

7. The use of claim 1, wherein the second medicament is to be administered at a dose of from 2 mg to 25 mg of the adapter.

8. The use of claim 1, wherein the second medicament is to be administered at a dose of about 0.4 mg, 0.8 mg, 1.6 mg, 2.8 mg, 3 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 40 mg, or 80 mg of the adapter.

9. The use of claim 1, wherein multiple doses of the second medicament are to be administered.

10. The use of claim 9, wherein the doses of the second medicament are to be administered daily.

11. The use of claim 9, wherein the doses of the second medicament are to be administered twice a day, three times a day, four times a day, every 12 hours, every 8 hours, every 6 hours, or every 4

hours.

12. The use of claim 9, wherein the doses of the second medicament are to be administered every other day, every three days, twice a week, or weekly.

13. The use of claim 9, wherein the doses of the second medicament are to be administered for between a week and two months.

14. The use of claim 9, wherein the doses of the second medicament are to be administered for 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, or 3 months.

15. The use of claim 9, wherein the doses of the second medicament are to be administered at a constant frequency over the period of treatment.

16. The use of claim 9, wherein the doses of the second medicament are to be administered at a frequency that decreases over the period of treatment.

17. The use of claim 1, wherein the at least one dose of the second medicament is to be administered intravenously.

18. The use of claim 1, wherein the dose of the first medicament and at least one dose of the second medicament are to be administered on the same day.

19. The use of claim 1, wherein the BCMA-related cancer is lymphoma or leukemia.

20. The use of claim 1, wherein the BCMA-related cancer is multiple myeloma.